Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this Expanded Access Program is to provide idebenone as a treatment for eligible participants with Duchenne Muscular Dystrophy before it is commercially available in the United States (U.S.) for the indication of DMD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)

NCT01027884

Muscular Dystrophy, Duchenne Ambulatory Care

COMPLETED PHASE3

Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)

NCT03603288

Duchenne Muscular Dystrophy

TERMINATED PHASE3

A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids

NCT02814019

Duchenne Muscular Dystrophy (DMD)

TERMINATED PHASE3

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

NCT03340675

Duchenne Muscular Dystrophy Cardiomyopathy Cardiomyopathy, Dilated

ACTIVE_NOT_RECRUITING PHASE2

Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)

NCT00758225

Duchenne Muscular Dystrophy

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Duchenne Muscular Dystrophy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Idebenone

900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documented diagnosis of DMD (severe dystrophinopathy) and clinical features consistent of typical DMD at diagnosis (i.e., documented delayed motor skills and muscle weakness by age 5 years) and who in the opinion of the Treating physician would benefit from treatment with idebenone. DMD should be confirmed by mutation analysis in the dystrophin gene or by substantially reduced levels of dystrophin protein (i.e., absent or \<5% of normal) on Western blot or immunostaining.
* Minimum 8 years old at Prescreening.
* PEF or FVC ≤80% and \>25% of predicted value based on most recent assessment noted in the patient's medical record and subsequently confirmed at the Enrollment Visit.
* Able to understand program requirements and swallow program medication.
* Signed and dated Informed Consent Form (to be obtained at the Enrollment Visit from patient or parent/legal guardian (if applicable) prior to performing any program-specific procedures and dispensing idebenone to the patient).

Exclusion Criteria

* Eligible for and able to participate in an ongoing clinical trial of idebenone.
* Is at high-risk of a fatal outcome from lung infection and/or advanced cardiomyopathy in the opinion of the Treating physician.
* Known moderate or severe impairment of hepatic function or severe impairment of renal function.
* Prior or ongoing medical condition or laboratory abnormality which in the Treating physician's opinion may put the patient at significant risk or may interfere significantly with the patient's participation in the program.
* Abuse of drugs or alcohol, which in Treating physician's opinion would interfere with the compliance to treatment.
* Known individual hypersensitivity to idebenone or to any of the ingredients/excipients of the program medication.

Minimum Eligible Age

8 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No